p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Condition(s):T-cell Lymphoma; Aggressive B-cell Lymphoma; Non-Hodgkin’s Lymphomas; Indolent B-cell LymphomaLast Updated:January 7, 2019Completed